Stock Analyses

Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.

All sectors 6,479 Financial Services 1,900 Healthcare 1,116 Technology 1,079 Industrials 668 Consumer Cyclical 490 Basic Materials 337 Consumer Defensive 248 Communication Services 213 Utilities 183 Energy 165 Real Estate 80

1,116 stocks · page 16 of 19

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.

SAB Biotherapeutics, Inc.

Sana Biotechnology, Inc.

SBC Medical Group Holdings Inc

Premium +51% Return to IV: -33.9%

Owner yield 6.1% 10-yr IRR 7.6% · steady

Market implies +6.3%/yr vs model +2.0% · above model

SBC Medical Group Holdings Inc

Deeply undervalued

Discount 91% Return to IV: +1,020.2%

Market implies -32.8%/yr vs model +7.3% · below model

Sunshine Biopharma Inc.

Market implies -50.0%/yr vs model +50.0% · below model

Sunshine Biopharma Inc.

Market implies -50.0%/yr vs model +50.0% · below model

Scilex Holding Co

Scilex Holding Co

Market implies -50.0%/yr vs model +25.0% · below model

Scinai Immunotherapeutics Ltd.

Market implies +150.0%/yr vs model +15.0% · above model

Scienture Holdings, Inc.

Market implies +41.0%/yr vs model +2.0% · above model

Market implies +23.2%/yr vs model +11.9% · above model

Stablecoin Development Corp

Market implies -2.9%/yr vs model +15.0% · below model

Schrodinger, Inc.

Deeply overvalued

Premium +332% Return to IV: -76.9%

Market implies +21.7%/yr vs model +16.7% · above model

Deeply overvalued

Premium +116% Return to IV: -53.7%

Market implies +4.5%/yr vs model +25.8% · below model

SELECT MEDICAL HOLDINGS CORP

Discount 9% Return to IV: +10.4%

Owner yield 12.6% 10-yr IRR 21.4% · steady

Market implies +2.6%/yr vs model +4.5% · in line

Senseonics Holdings, Inc.

Deeply overvalued

Premium +262% Return to IV: -72.4%

Market implies +22.5%/yr vs model +50.0% · below model

Discount 7% Return to IV: +7.0%

Market implies +6.1%/yr vs model +10.0% · below model

Serina Therapeutics, Inc.

Market implies +85.0%/yr vs model +2.0% · above model

SERA PROGNOSTICS, INC.

Market implies +116.1%/yr vs model +2.0% · above model

Sight Sciences, Inc.

Market implies +45.4%/yr vs model +12.1% · above model

Sagimet Biosciences Inc.

Market implies +81.2%/yr vs model +15.0% · above model

SpyGlass Pharma, Inc.

Surgery Partners, Inc.

Deeply undervalued

Discount 52% Return to IV: +107.7%

Owner yield 11.1% 10-yr IRR 24.3% · moderate

Market implies -2.6%/yr vs model +10.3% · below model

Sotera Health Co

Deeply overvalued

Premium +178% Return to IV: -64.1%

Market implies +19.9%/yr vs model +7.0% · above model

Shuttle Pharmaceuticals Holdings, Inc.

SHOULDER INNOVATIONS, INC.

Deeply undervalued

Discount 61% Return to IV: +156.6%

Market implies -17.7%/yr vs model +49.6% · below model

Premium +68% Return to IV: -40.6%

Market implies +3.9%/yr vs model +22.2% · below model

SIGA TECHNOLOGIES INC

Deeply undervalued

Discount 61% Return to IV: +156.6%

Market implies -11.2%/yr vs model +3.5% · below model

Silo Pharma, Inc.

Market implies +83.2%/yr vs model +15.0% · above model

Sintx Technologies, Inc.

Market implies +29.1%/yr vs model +13.9% · above model

Sionna Therapeutics, Inc.

SkinHealth Systems Inc.

Deeply undervalued

Discount 54% Return to IV: +118.6%

Market implies -10.5%/yr vs model +5.6% · below model

Skye Bioscience, Inc.

Solid Biosciences Inc.

Market implies +70.7%/yr vs model +15.0% · above model

Sol-Gel Technologies Ltd.

Market implies +32.1%/yr vs model +2.0% · above model

Silence Therapeutics plc

Market implies +129.4%/yr vs model +2.0% · above model

SELLAS Life Sciences Group, Inc.

Market implies +114.4%/yr vs model +15.0% · above model

Silexion Therapeutics Corp

Silexion Therapeutics Corp

Summit Therapeutics Inc.

Market implies +150.0%/yr vs model +15.0% · above model

Sanara MedTech Inc.

Deeply undervalued

Discount 49% Return to IV: +97.5%

Market implies -13.4%/yr vs model +43.8% · below model

SONIDA SENIOR LIVING, INC.

Deeply undervalued

Discount 24% Return to IV: +31.8%

Market implies -8.9%/yr vs model +12.9% · below model

Syndax Pharmaceuticals Inc

Market implies +18.0%/yr vs model +5.4% · above model

SOLIGENIX, INC.

Market implies +38.9%/yr vs model +15.0% · above model

SMITH & NEPHEW PLC

Sonoma Pharmaceuticals, Inc.

Deeply undervalued

Discount 88% Return to IV: +735.6%

Market implies -48.8%/yr vs model +2.0% · below model

Sensei Biotherapeutics, Inc.

Senti Biosciences Holdings, Inc.

Market implies +96.6%/yr vs model +2.0% · above model

SANUWAVE Health, Inc.

Deeply undervalued

Discount 83% Return to IV: +481.3%

Market implies -34.8%/yr vs model +40.3% · below model

Synergy CHC Corp.

Market implies -50.0%/yr vs model +2.0% · below model

Discount 11% Return to IV: +12.4%

Owner yield 5.2% 10-yr IRR 6.7% · steady

Market implies +1.5%/yr vs model +3.6% · in line

Safe Pro Group Inc.

Market implies +79.1%/yr vs model +2.0% · above model

SPRUCE BIOSCIENCES, INC.

Market implies +33.9%/yr vs model +15.0% · above model

Spero Therapeutics, Inc.

Market implies -2.7%/yr vs model +42.3% · below model

ARS Pharmaceuticals, Inc.

Premium +13% Return to IV: -11.8%

Market implies +3.6%/yr vs model +50.0% · below model

Seaport Therapeutics, Inc.

Sarepta Therapeutics, Inc.

Discount 8% Return to IV: +8.2%

Market implies +3.4%/yr vs model +32.1% · below model